Research Paper Volume 12, Issue 7 pp 6352—6369

FAM46C inhibits cell proliferation and cell cycle progression and promotes apoptosis through PTEN/AKT signaling pathway and is associated with chemosensitivity in prostate cancer

Figure 1. FAM46C expression was decreased in prostate cancer tissues. FAM46A, FAM46B FAM46C and FAM46D mRNA expression levels in prostate cancer tissues (n=52) and noncancerous prostate tissues (n=497) from TCGA database (A), and that in benign prostatic hyperplasia tissues and prostate cancer tissues with different Gleason scores (n=15 per group) from hospital cohort were measured by qPCR (B). (C) FAM46C mRNA expression levels in several cancer types compared with the corresponding normal controls, including bladder carcinoma (BLCA), breast carcinoma (BRCA), cervical cancer (CESC), cholangiocarcinoma (CHOL), colon and rectal adenocarcinoma (COAD), esophageal cancer (ESCA), head and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), kidney papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), pheochromocytoma and paraganglioma (PCPG), prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), sarcomas (SARC), skin cutaneous melanoma (SKCM), thyroid carcinoma (THCA), thymoma (THYM), stomach adenocarcinoma (STAD) and uterine cervical and endometrial carcinoma (UCEC), from TCGA database. Blue, normal samples. Red, tumor samples. (D) FAM46C mRNA expression levels in prostate cancer tissues and corresponding adjacent noncancerous prostate tissues (n=30) from hospital cohort were measured by qPCR. (E) Relative mRNA expression of FAM46C in 30 cases of prostate cancer patients (-log2T/N). (F) FAM46C expression levels in human prostate cancer cell lines (LNCaP, PC-3, 22RV1 and DU145) and human prostate epithelial cell line RWPE-2 were measured by qPCR and western blot. ***P < 0.001.